---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-263540"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:41:16.351019+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kymera Q3 net loss $82.2M; KT-621 Phase 1b AD data due Dec 2025

## Summary
- Net loss $82.2M in Q3 2025 vs $62.5M in Q3 2024; R&D expenses rose to $74.1M.
- Cash $978.7M as of Sept 30; runway into H2 2028 beyond multiple pipeline milestones.
- KT-621 Phase 1b AD trial (BroADen) enrollment complete; top-line data expected Dec 2025.
- KT-621 Phase 2b AD trial (BROADEN2) initiated; asthma Phase 2b (BREADTH) on track for 1Q26.
- KT-579 (IRF5) IND-enabling studies completed; Phase 1 planned for early 2026.

## SEC filing metadata
- accession: 0001193125-25-263540
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312525263540/0001193125-25-263540-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312525263540/kymr-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-263540
- JSON: https://secwatch.observer/filing/0001193125-25-263540.json
- Plain text: https://secwatch.observer/filing/0001193125-25-263540.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.